Benevira Delivers Breakthrough Investor Presentation at The New York Venture Summit
NEW YORK – September 6, 2023 – Benevira recently became one of 200 companies worldwide to earn a coveted presentation slot at the 23rd annual New York Venture Summit. The New York-based event connects founders of the hottest venture backed, emerging and early-stage companies with an exclusive audience of venture capitalists, corporate investors, private investors, investment bankers, and strategic partners.
POSITIVE DIAGNOSTIC RESULTS
Benevira Announces Positive Preclinical Data for its Novel COVID-19 Treatment.
NEW YORK - May 24, 2022 - Benevira, a global synthetic biology company focused on treating viral disease, today announced positive preclinical safety and efficacy data on β521, a novel SARS-CoV-2 therapy, demonstrating robust tolerability and efficacy against several SARS-CoV-2 variants. The results showed that β521 was 99% effective in preventing SARS-CoV-2 infections in Vero cells grown in the presence of a high titer of delta or omicron variants. In addition, 100% tolerability was observed for β521 in New Zealand rabbits at a maximum dosing concentration. β521 is the lead candidate in the company’s therapeutics pipeline developed to target functional components of viruses that are unlikely to evolve, thus retaining their efficacy as potential new variants emerge.
Benevira Meets Cyprus’ President and Minister of Health
November 3, 2022 - Benevira had the pleasure of attending a dinner at the Presidential Palace in Nicosia, Cyprus. Our CEO, Patricia Kitchen, had the opportunity to meet with the President of the Republic of Cyprus, H.E. Nicos Anastasiades (top picture) and the Minister of Health, Mr. Michalis Hadjipantela (bottom-right) while continuing discussions of the technology being developed by Benevira for the protection against SARS-CoV-2.